Clinical Research Directory
Browse clinical research sites, groups, and studies.
Avoiding Anticoagulation After IntraCerebral Haemorrhage
Sponsor: University Hospital, Lille
Summary
Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an intracerebral haemorrhage. Roughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid anticoagulation and LAAC.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2019-01-17
Completion Date
2029-12
Last Updated
2026-04-07
Healthy Volunteers
No
Interventions
Apixaban 5 MG
Apixaban 5mg x 2 during 24 months
left atrial appendage closure
left atrial appendage closure
Locations (3)
Hôpital Roger Salengro, CHU
Lille, France
GHICL
Lomme, France
CH De Tourcoing
Tourcoing, France